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Cross sectional evaluation of the 
gut-microbiome metabolome axis 
in an Italian cohort of IBD patients
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Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract of 
uncertain origin, which includes ulcerative colitis (UC) and Crohn’s disease (CD). The composition 
of gut microbiota may change in IBD affected individuals, but whether dysbiosis is the cause or the 
consequence of inflammatory processes in the intestinal tissue is still unclear. Here, the composition 
of the microbiota and the metabolites in stool of 183 subjects (82 UC, 50 CD, and 51 healthy controls) 
were determined. The metabolites content and the microbiological profiles were significantly different 
between IBD and healthy subjects. In the IBD group, Firmicutes, Proteobacteria, Verrucomicrobia, and 
Fusobacteria were significantly increased, whereas Bacteroidetes and Cyanobacteria were decreased. 
At genus level Escherichia, Faecalibacterium, Streptococcus, Sutterella and Veillonella were increased, 
whereas Bacteroides, Flavobacterium, and Oscillospira decreased. Various metabolites including 
biogenic amines, amino acids, lipids, were significantly increased in IBD, while others, such as two 
B group vitamins, were decreased in IBD compared to healthy subjects. This study underlines the 
potential role of an inter-omics approach in understanding the metabolic pathways involved in IBD. 
The combined evaluation of metabolites and fecal microbiome can be useful to discriminate between 
healthy subjects and patients with IBD.
Inflammatory bowel disease (IBD) represents a group of chronic disorders that affect one or more parts of the 
intestine. Crohn’s disease (CD) and ulcerative colitis (UC) are considered the two major clinically defined forms1. 
IBD affects 1.5 million Americans, 2.2 million European, and several hundred thousand elsewhere in the world2. 
The highest incidences of CD and UC have been reported in northern Europe, the United Kingdom, and North 
America with a greater incidence of UC than CD3. However, the incidence of IBD is increasing in emerging pop-
ulations such as Asian, probably due to changes in environmental factors. The peak incidence of IBD is between 
the second to fourth decades of life4. Incidence in established populations is similar in men and women, but is 
influenced by race and ethnicity.
The etiology of IBD is multifactorial and only partially known, resulting from genetic, immunological and 
environmental factors. The most accepted hypothesis for the pathogenesis of IBD is the development of an over 
aggressive adaptive immune response mediated by T cells to a subset of commensal enteric bacteria in genetically 
susceptible hosts5. Moreover, environmental factors, such as diet, life style and smoking play crucial roles in the 
development of disease6. In particular, the relationship between the metabolome and microbiota, such the asso-
ciation between butyrate and Ruminococcus and Butyricicoccus bacteria, has been shown to be of fundamen-
tal importance in elucidating IBD pathogenesis and in establishing targeted therapeutic strategies7,8. Twin-pair 
studies have shown differences in fecal metabolites and microbiome between patients with Crohn disease and 
their healthy siblings9,10. Moreover, the detection of metagenomics differences yielded the identification of 
disease-related biomarkers, which presumably derive from disease-associated alterations in the microbial flora11.
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In this study, we have used a combined metabolomics and metagenomics approach to study the differences 
between CD and UC, and understand how these two pathologies arise. Fecal samples of IBD patients, with either 
CD and UC, and healthy subjects were analyzed by the means of metabolomics and metagenomics. Nuclear 
magnetic resonance spectroscopy (1H-NMR), gas chromatography mass spectrometry (GC-MS) and liquid chro-
matography in combination with quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) were used to 
construct the metabolic profile of fecal samples, and 16 S rRNA gene sequencing data were produced from each 
biospecimen by the Illumina Hi-Seq platform to reveal the gut microflora composition. Finally, we investigated 
the correlation between measured metabolites and identified bacteria to better define the gut-microbiome metab-
olome during the development of IBD.
Results
Microbiota analysis. A total of 18,899,323 sequencing reads were obtained from the 183 fecal samples. 
The numbers of OTUs varied from 4,901 to 672,146. The mean differences in the α-Shannon values between 
the CTLs, the IBD, and the CD and UC groups were always statistically different (Fig. 1). The majority of the 
OTU sequences were assigned to seven main phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, 
Verrucomicrobia, Cyanobacteria and Fusobacteria. In Fig. 1 the relative abundance and frequency of the OTUs 
at the phylum level are shown for those OTUs that have at least 0.1% abundance. In the IBD group compared 
to the CTLs group, Firmicutes (46.39% vs 38.99%), Proteobacteria (10.49% vs 6.54%), Verrucomicrobia (1.90% 
vs 1.02%), and Fusobacteria (0.72% vs 0.19%) were significantly increased, whereas Bacteroidetes (33.63% vs 
47.45%) and Cyanobacteria (0.73% vs 0.51%) were decreased. The Firmicutes:Bacteroidetes ratio was 0.82 in the 
CTLs group, but 1.38 in IBD patients (Fig. 1a).
In CD patients only Bacteriodetes (32.83% vs 47.45%), Proteobacteria (13.67% vs 6.54%), Verrucomicrobia 
(3.76% vs 1.02%) and Cyanobacteria (0.38% vs. 0.73%) showed the same evidence of variation between the 
groups, and in UC patients only Proteobacteria did not attain the same significant difference. Additionally, in 
this group, Actinobacteria phylum (8.42% vs 2.26%) was significantly increased compared to CTLs (Fig. 1b,c).
The relative abundances and frequency of the OTUs at order (Supplementary 1, Figs S1,2) and genus level 
(Supplementary 1, Fig. S3) are shown. At genus level, Escherichia, Faecalibacterium, Streptococcus, Sutterella and 
Veillonella all significantly increased in the IBD group, whereas Bacteroides, Flavobacterium, and Oscillospira 
geni all decreased. In CD patients, only Escherichia and Veillonella significantly increased, and, among the gen-
era that decreased, also Prevotella decreased significantly. Interestingly, in this group the Faecalibacterium genus 
decreased compared to the control group, as opposed to what was observed in IBD as a whole and in the UC 
group. In UC patients, increase of the Faecalibacterium and decrease of the Oscillospira genera, respectively, were 
not statistically significant (Fig. 2).
Finally, in Fig. 3 the distribution of the OTUs at the species level is shown for those that appeared increased 
and decreased in the CD and UC groups, respectively. In the CD group, 25 species increased and 22 species 
decreased, respectively, whereas in the UC group, 18 species increased and 17 species appeared reduced, respec-
tively. Amongst Proteobacteria, Escherichia alberti resulted much more abundant than in controls (4.61% vs 
0.24% in CD; 3.28% vs 0.24% in UC), and, among Bactroidetes, Prevotella copri was the main species reduced 
(0.02% vs 3.91% in CD; 0.68% vs 3.91% in UC) in both patient groups.
Neither the diet nor the activity of disease did affect the microbiome composition. Regarding the localization 
of the disease, only the relative abundance of Fusobacteria correlated with the colon vs. the ileum localization 
of the Crohn’s disease. Finally, a significant correlation between abundance of Firmicutes and Verrucomicrobia 
and medications was observed in CD group, and between Actinobacteria and therapy in the UC group (see 
Supplementary 1, Table S1a,b,c).
Metabolomics analysis. GC-MS analysis. The OPLS-DA score plot demonstrates clear separation 
between both CD patients and healthy controls and UC patients and healthy controls (Fig. 4a,b). The quality of 
the models was evaluated using the corresponding Partial Least Square Discriminant Analysis (PLS-DA) models 
using a 7-fold cross-validation and permutation test over 400 times (Supplementary 1, Table S2). Moreover, to 
investigate if we could distinguish between the two pathological conditions, an OPLS-DA model was created. This 
comparison did not show good results, indicating an intrinsic similarity in metabolic profiles (Supplementary 1, 
Table S1). Discriminant metabolites were highlighted by the means of an S-plot and a Mann-Whitney test was 
carried out to find significant differences between the classes.
Fourteen metabolites were detected to be responsible for the separation of the CD patients from the healthy 
control group (Fig. 5). Of these, eight were significantly increased in CD patients (alanine, beta-alanine, phe-
nylacetic acid, 4-hydroxyphenylacetic acid, glyceric acid, phenylethylamine, putrescine and cadaverine) and 
six metabolites significantly decreased in CD patients (nicotinic acid, pantothenic acid, 3-methyladipic acid, 
5β-coprostanol, 3-hydroxybutyric acid and hydrocinnamic acid).
Regarding the comparison between UC patients and healthy controls, sixteen metabolites were able to 
discriminate between the two groups (Fig. 6), nine of which were in common with the CD patients-healthy 
controls comparison. Six metabolites significantly, 4-hydroxyphenylacetic acid, glucose, cadaverine and 
5-aminovaleric acid), while 10 metabolites significantly decreased in UC patients (nicotinic acid, pantothenic 
acid, 3-methyladipic acid, pyroglutamic acid, 5β-coprostanol, 3-hydroxybutyric acid, hydrocinnamic acid, lin-
oleic acid, sebacic acid and tricarballylic acid).
1H-NMR analysis. Spectral resonances were assigned to individual metabolites on the basis of data published 
in the literature12,13 and using the 500 MHz library from Chenomx NMR suite 7.1 (Chenomx Inc., Edmonton, 
Alberta, Canada). OPLS-DA score plots demonstrated good separation between the healthy control group 
and CD and UC patients, respectively (Fig. 4c,d). However, just as with GC-MS data OPLS-DA was not able 
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to distinguish between the two pathological conditions (UC and CD), indicating an intrinsic similarity in met-
abolic profiles (Supplementary 1, Table S2). In order to understand the actual trend of the metabolites, their 
relative concentrations were determined using the Chenomx NMR suite 7.1. The CD patients had a lower 
content of 2-hydroxy-3-methylvaleric acid, citric acid, and methylamine, but a higher content of cadaverine, 
Figure 1. Microbiome taxonomic composition in IBD, CD, UC patients and control subjects (CTLs). Relative 
abundance at OTU frequency at phylum level, Firmicutes/Bacteroidetes ratio, and α-diversity are shown. 
The data are filtered by a frequency higher than 0.1% (a). Relative abundance of phyla and OTU frequency 
are shown in CD (*) (b) and UC (*) (c) patients compared to controls (CTLs, ^). Significant differences with 
p < 0.05 are shown. *patients; ^controls.
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putrescine and phenylalanine than the healthy controls (Fig. 5). The UC patients had significantly lower content 
of 2-hydroxy-3-methylvaleric acid, glutamic acid, citric acid, methylamine, but a higher content of cadaverine, 
trimethylamine-N-oxide (TMAO), tyramine and phenylalanine than the healthy controls (Fig. 6).
LC-QTOF-MS analysis. Peaks were identified and attributed to endogenous metabolites that included steroids, 
ceramides (Cer), phosphatidylserines (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), diacylg-
lycerols (DG), triacylglycerol (TG), n-acylphosphatidylethanolamines (NAPE) and other lipids.
OPLS-DA analysis displayed a clear separation between healthy subjects and both pathological classes (CD 
and UC) (Fig. 4e). As well as GC-MS and 1H-NMR analysis, the comparison between the two pathological classes 
did not show good separation (Supplementary 1, Table S2).
Seventeen metabolites were interpreted to be different between CD patients and healthy controls (Fig. 5). 
Using MS/MS fragmentation data, we were able to annotate six of them. DG (18:0/22:2) significantly increased 
in CD patients, while urobilin, PC (16:0/3:1), urobilinogen, PA (19:0/16:1) and PS (22:2/18:0) were found to be 
decreased.
Comparing UC patients with healthy controls, sixteen metabolites differentiated between the two classes. Nine 
of these were in common with the CD patients-healthy controls comparison. In particular, DG (16:0/18:2), DG 
(18:0/22:2) and NAPE (18:1/16:1/18:0) were identified to be significantly increased in UC patients feces, while PC 
(16:0/3:1), urobilinogen, PC (22.2/14:1) and Cer (18:1/22:0) were decreased in UC patients (Fig. 6).
Overall, neither the diet, nor the therapy, or the localization of the disease have had significant effect on the 
metabolome composition. In fact, the PLS-DA analysis for both UC and CD groups provided poor statistically 
significant results (see Supplementary 1, Table S3).
Pathways analysis. Metabolic pathways were built using the MetaboAnalyst version 3.014; only metabolites with 
significantly different (p < 0.05) concentrations between healthy patients and patients with CD and UC were 
used. The analysis showed how CD and UC significant metabolites were involved in different pathways as pheny-
lalanine, glutathione and beta-alanine metabolism and pantothenate and CoA biosynthesis. The first three path-
ways are part of the amino acids metabolism while the last is involved in the metabolism of cofactor and vitamins. 
Moreover, the analysis demonstrated as UC metabolites were also implicated in methane metabolism and lysine 
degradation (Fig. 7a,b). The first is again comprised in the amino acids metabolism while the latter is classified as 
a part of the energy metabolism.
Figure 2. Microbiome taxonomic composition at genus level in CD, UC and controls subjects. Relative 
abundance of genera and OTU frequency are shown in CD (*) and UC (*) patients compared to controls 
(CTLs, ^). Significant differences with p < 0.05 are shown.
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Correlation between metabolome and microbiome. The observation was restricted to the microbial 
genera whose relative abundance resulted statistically different among the different groups of subjects and to 
metabolites that were characterized by the highest discriminative power among the patients and healthy controls 
(Supplementary 1, Fig. S4).
The Spearman correlation analysis revealed a strong association between five bacterial genera with 10 discri-
minant metabolites in CD patients (Fig. 8a). The most correlated genus was Oscillospira, particularly with hydro-
cinnamic acid, 3-methyladipic acid, 5β-coprostanol, citric acid, methylamine, 2-hydroxy-3-methylvaleric acid, 
PC (16:0/3:1) and urobilin (all positive correlations), while the genus negatively correlated with cadaverine and 
putrescine. In addition, the Faecalibacterium genus negatively correlated with the two biogenic amines, cadav-
erine and putrescine, while only nicotinic acid positively correlated. The Escherichia genus negatively correlated 
with nicotinic acid, citric acid and PC (16:0/3:1) and positively correlated with cadaverine. Lastly, a positive cor-
relation was detected between the Flavobacterium genus and 5β-coprostanol and between the Veillonella genus 
and cadaverine.
The Spearman correlation coefficient was less strong for UC than for CD patients (Fig. 8b). Only three bac-
terial genera correlated with six metabolites. Particularly, a strong positive correlation was observed between 
Flavobacterium genus and 3-methyladipic acid, 2-hydroxy-3-methylvaleric acid, citric acid, methylamine and 
PC (16:0/3:1), while this genus negatively correlated with trimethylamine-N-oxide (TMAO). UC patients also 
presented correlations between Oscillospira genus and 3-methyladipic acid, 2-hydroxy-3-methylvaleric acid and 
citric acid, and between Veillonella genus and citric acid.
Fifteen bacterial species showed a good correlation with 14 discriminant metabolites in Crohn disease 
patients (Fig. 8c, and Supplementary 1, Fig. S5). Seven species, Faecalibacterium prausnitzii, Oscillospira eae, 
Oscillospira guillermondii, Anaerobranca zavarzinii, Veillonella montpellierensis, Ruminococcus albus and 
Alkaliphilus crotonatoxidans belonging to the Firmicutes phylum, four, Desulphonauticus Autotrophicus, 
Serratia entomophila, Escherichia albertii and Candidatus Endobugula sertula to the Proteobacteria phylum, 
three, Dysgonomonas wimpennyi, Rikenella microfusus and Parabacteroides johnsonii to the Bacteroidetes phy-
lum and finally only one, Bifidobacterium adolescentis to the Actinobacteria phylum. In particular, a strong 
positive correlation was seen between Oscillospira eae and 5β-coprostanol, 3-methyladipic acid, citric acid, 
Figure 3. Relative abundance of species in CD e UC patients compared to controls subjects. OTU frequency 
of species higher than 0.01% are indicated as expanded or contracted in patients groups and controls subjects. 
*Indicates that only levels of significance with p < 0.05 for the species indicated are shown.
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methylamine, 2-hydroxy-3-methylvaleric acid, PC (16:0/3:1) and urobilin; between Oscillospira guillermondii 
and 5β-coprostanol, methylamine and PC (16:0/3:1); and finally between Desulphonauticus autotrophicus and 
5β-coprostanol, 3-methyladipic acid, citric acid, methylamine and PC (16:0/3:1). On the other hand, a strong 
negative correlation between Faecalibacterium prausnitzii and phenylethylamine and between Desulphonauticus 
autotrophicus and putrescine and cadaverine was documented.
Evaluation of the metabolome-species relationship in UC patients showed good correlations between 
Pedobacter kwangyangensisvs and Dysgonomonas wimpennyi and 3-methyladipic acid, 5ß-Coprostanol, 
2-hydroxy-3-methylvaleric acid, citric acid and methylamine, while only 3-methyladipic acid positively corre-
lated with Akkermansia muciniphila species. A negative correlation was detected between TMAO and Pedobacter 
kwangyangensisvs, Dysgonomonas wimpennyi and Alkaliphilus crotonatoxidans species (Fig. 8d).
Discussion
It has been established that the gut microbiota is dysregulated in IBD, which leads to the modification of the 
bacterial metabolic activity15. In the clinical management of IBD, there are significant, inherent challenges in 
elucidating whether dysbiosis contributes to disease pathogenesis or whether, by contrast, it could be a second-
ary change associated with the inflammatory process, which may be driven by host genetics and environmental 
factors like diet.
In this study, we have applied a dual-omics approach to improve our current understanding of IBD, and in 
particular the host-microbial interactions, and the functional aspects of the gut microbiota.
Whereas it has been reported previously in IBD that there is a decrease in Firmicutes and Actinobacteria 
abundance, along with high levels of Proteobacteria compared to healthy subjects16, we did not find this in our 
patient cohort apart from the increase in Proteobacteria. Our cohort demonstrated, instead, increased levels 
of Firmicutes in IBD (with statistical significance only in the UC group) and Actinobacteria (with statistical 
significance in UC patients). Since in our analysis the relative abundance of Firmicutes and Actinobacteria also 
correlated with the IBD therapy, this aspect should be further investigated.
The bacterial complexity was significantly lower in IBD, CD and UC patients compared to control subjects, as 
previously reported. Taken together, these data may reflect at least in part the results obtained from the metab-
olomics analysis, which revealed characteristic clustering profiles among healthy subjects and patient categories 
(IBD, CD, and UC). Two biogenic amines, cadaverine and putrescine were found significantly increased in CD 
Figure 4. OPLS-DA score plots. In the first column CD vs healthy comparisons are shown while the second 
column of plots contains UC vs healthy comparisons. Plots were obtained with GC-MS (a,b), 1H-NMR (c,d) 
and LC-MS/MS QTOF analysis (e,f).
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patients compared to healthy subjects. Polyamines are formed mainly by the decarboxylation of certain amino 
acids or by transamination of aldehydes or ketones, and are produced both by the host and by intestinal flora 
bacteria. While their specific role is still largely unknown, polyamines are involved in numerous physiological 
processes such as the preservation of membrane integrity and nucleic acids metabolism. Furthermore, they have 
a crucial role in the regulation of gene expression and translation17. Several studies demonstrated how polyamines 
are necessary for the division of epithelial cells18–21. In fact, the normal growth of the intestinal mucosa depends 
Figure 5. Statistically significant metabolites in CD vs healthy comparison. Discriminant metabolites 
obtained with the MVA, underwent to a Mann-Whitney test to determine which metabolites were statistically 
significantly variated. The resulted metabolites obtained are shown. Relative concentrations are represented in 
the y axis. * And **Indicates levels of significance with p < 0.05 and <0.01, respectively.
www.nature.com/scientificreports/
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on the polyamines availability within the cell division crypts, and such substrates could be synthesized endoge-
nously or absorbed at the lumen level. Elevated levels of polyamines seem to have a toxic effect and are associated 
with several diseases. It is believed that at the basis of this toxicity there is the oxidative stress caused by poly-
amines catabolism22. In our study, the Spearman correlation analysis demonstrated that the increase of the two 
polyamines negatively correlated with the amount of two bacterial genera belonging to the Firmicutes phylum, 
Faecalibacterium and Oscillospira. Moreover, cadaverine levels were also directly associated with the abundance 
Figure 6. Statistically significant metabolites in UC vs healthy comparison. Discriminant metabolites 
obtained with the MVA, underwent to a Mann-Whitney test to determine which metabolites were statistically 
significantly variated. The resulted metabolites obtained are shown. Relative concentrations are represented in 
the y axis. * And **Indicates levels of significance with p < 0.05 and <0.01, respectively.
www.nature.com/scientificreports/
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of another Firmicutes genus, Veillonella, and the Proteobacterium Escherichia. Interestingly, Oscillospira and 
Faecalibacterium genera seems to have a protective action against inflammation23.
The increase of glyceric acid in the stool of patients with CD could be due to a release of triacylglycerols asso-
ciated with the colon mucosa24. The high levels of amino acids, such as alanine, beta-alanine and phenylalanine in 
the feces of CD patients might, in part, result from malabsorption due to inflammation in these patients, or reflect 
an increase of the producing bacteria.
Two group B vitamins, nicotinic acid and pantothenic acid, significantly decreased in feces of CD patients25. 
Some studies report that pantothenic acid may have a protective effect against oxidative stress in mammalian 
tissues26. It seems that nicotinic acid might also have a protective effect on the mucosa of the colon, reducing 
Figure 7. Relevant metabolic pathways involved in CD (a) and in UC (b).
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inflammation27. The decreased levels of nicotinic acid in patients with CD may be due to a smaller presence of 
nicotinic acid producing bacteria. Decreased levels of this vitamin directly correlated with the reduced amount 
of the Faecalibacterium bacteria, particularly, with the decreased abundance of Faecalibacterium prausnitzii. It 
has already been demonstrated that Faecalibacterium has a protective role against inflammation of the colon 
mucosa28. Faecalibacterium prausnitzii abundance also inversely correlated with phenylethylamine. This amino 
acid is biosynthesized from the amino acid L-phenylalanine by enzymatic decarboxylation via the enzyme aro-
matic L-amino acid decarboxylase29. In addition to its presence in mammals, phenethylamine is found in many 
other organisms and foods, such as chocolate, especially after microbial fermentation. The concentration of phe-
nylethylamine increased in feces of CD patients, suggesting that the depletion of Faecalibacterium prausnitzii 
could lead to an increase of some amine, which in turn could play a role in the pathogenesis of an inflammatory 
process30.
The amount of methylamine decreased in the aqueous fecal water extracts of patients with CD. This com-
pound is derived from intestinal degradation of food components such as choline and carnitine by microbiota. 
The depletion of this microbiota-related metabolite correlated with the decrease of Oscillospira amount in feces, 
confirming the perturbation of the microbial homeostasis in patients with CD31.
In our study, 5β-coprostanol decreased in feces of CD patients. 5β-coprostanol derives from the catabolism of 
cholesterol by gut microbiota32. Again, the reduced amount of this metabolite correlated with the Oscillospira and 
Flavobacterium decrease in feces of CD patients. The low abundance of Oscillospira genus bacteria correlated also 
to the reduced levels of hydrocinnamic acid, 3-methyladipic acid, citric acid and 2-hydroxy-3-methylvaleric acid, 
confirming again the importance of this bacterium in the gut metabolism and wellness.
As several studies demonstrated, diacylglycerols, such as DG (18:0/22:2), are involved in the activation of the 
protein kinase C (PKC) in many cell types33,34. The upregulation of DG (18:0/22:2) in CD could suggest a mod-
ification of the protein kinase C (PKC) pathway. PKC plays a crucial role in many aspects of the gastrointestinal 
tract homeostasis, taking part in many physiological and pathological processes such as development, inflamma-
tion and tumorigenesis35.
Several others lipids, such as urobilin, urobilinogen, PC (16:0/3:1), PA (19:0/16:1) and PS (22:2/18:0), were 
found to be decreased in the same patients. Urobilinogen and urobilin are open tetrapyrroles deriving from 
Figure 8. Inter-omic Spearman rank correlation between metabolites and bacterial genera and species. 
Spearman correlation between statistically different metabolites and bacterial genera was calculated both for 
CD (a) and UC (b). Spearman correlation between statistically different metabolites and bacterial species was 
calculated both for CD (c) and UC (d). Correlations with an r coefficient >0.5 are shown.
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bilirubin catabolism by gut microorganisms and are excreted with urines and feces36. The urobilin level reduction 
might be due to a significantly lower conversion rate of urobilin in CD patients as compared to the controls and 
this could indicate an altered entero-metabolic function in these patients37. The downregulation of phosphocho-
lines, such as PC (16:0/3:1), could reflect a defect of PC synthesis or secretion. It has been known that several 
pathologies, like IBD or cancer, are correlated to the phospholipids pathways38. Cytosolic phospholipase A2 is 
activated by low concentration of Ca2+, and during this activation the lipase is transferred from the cytosol to the 
cell membrane to initialise the arachidonic acid cascade producing many inflammatory mediators39.
In addition to the previously described metabolites, fecal extracts derived from UC patients showed an increase 
in tyramine, TMAO, glycine, glucose, 5-aminovaleric acid, DG (16:0/18:2) and NAPE (18:1/16:1/18:0), and 
a decrease in glutamic acid, pyroglutamic acid, linoleic acid, sebacic acid and trycarballylic acid, PC (22.2/14:1), 
and Cer (18:1/22:0). Furthermore, in UC patients there was a decrease in 3-methyladipic acid, 2-hydroxy-
3-methylvaleric acid, citric acid, methylamine and PC (16:0/3:1). The reduced levels of all these metabolites 
strongly correlated with the lower abundance of the Flavobacterium genus, belonging to the Bacteroidetes phy-
lum. This genus also negatively correlated with TMAO levels. TMAO is generated by anaerobic bacteria through 
the digestion of dietary phosphatidylcholine and carnitine in a microbial-mammalian co-metabolic pathway. One 
previous study has found that plasma TMAO levels were significantly lower in UC population, suggesting that 
TMAO may be clinically useful in monitoring UC patients40.
3-Methyladipic acid, 2-hydroxy-3-methylvaleric acid and citric acid levels also positively correlated to 
Oscillospira abundance, suggesting a putative anti-inflammatory effect of Oscillospira in UC.
As previously described in the results, glucose increased in feces of UC patients. Glucose serves as an energy 
source for normal intestinal mucosa and its utilization is reduced during malnutrition and starvation, a common 
symptom observed in UC41. High levels of glucose thus indicate the inability of the colonic mucosal cells to utilise 
it for energy requirements.
The increased levels of NAPE (18:1/16:1/18:0) in UC patients suggest a modification of endocannabinoid 
system that has been demonstrated to be involved in the regulation of numerous gastrointestinal functions 
including gut homeostasis, modulating gastrointestinal motility, visceral sensation, and inflammation. Moreover, 
these metabolites have been recently implicated in IBD pathogenesis42,43. NAPEs are synthesized in the small 
intestine and after their synthesis are converted to the active NAEs. NAPEs are also converted into phosphatidic 
acid and anandamide by N-acylphosphatidylethanolamine-hydrolysing phospholipase D enzyme. Anandamide 
and 2-arachidonoylglycerol are endogenous bioactive lipids that bind and activate the cannabinoid recep-
tors44. Decreased levels of anandamide and its synthesizing enzyme were found in the intestinal biopsies of UC 
patients45.
Our study combined the quantitative analysis of metabolites and microbiome in feces samples patients with 
CD and UC, and showed that this approach can be used to discriminate between healthy and diseased subjects. 
The results suggest that the detection of gut microbiota biomarkers in association with the comparative analysis 
of metabolites related to microbial metabolism or microbial-host co-metabolism could help to better understand 
the pathogenesis of IBD, and lead to the development of strategies for the early disease prediction and promote 
the development of novel targeted therapies.
Methods
Patients. The study was conducted in accordance with the principles of good clinical practice. The institu-
tional ethics committee (Azienda Ospedaliero-Universitaria di Cagliari, Italy) approved the study, and written 
informed consent was obtained from each participant. All eligible UC (n = 82) and CD (n = 50) patients had their 
diagnosis confirmed by endoscopic, histological and radiographic data. Disease activity was verified by well-es-
tablished criteria, including endoscopic grading according to the CDEIS and Rutgeerts scores for CD patients, 
and the Mayo score for UC patients46 (see Supplementary 1, Tables S5, S6). The healthy volunteers (n = 51) were 
recruited locally (Table 1). The exclusion criteria were as follows: (a) age >80 or <20 years; (b) use of antibiotics 
or probiotics in the last three months and (c) pregnancy. Each participant was given a sample collection kit with 
instructions. Hence, one fecal sample from each subject was collected and subsequently delivered to the labora-
tory within 3 hours. Samples were stored at −80 °C until use.
Gut microbiota analysis. DNA extraction and quantification. DNA extraction from thawed fecal sam-
ples was performed using the QIAamp DNA stool MiniKit according to the instructions of the manufacturer 
(Qiagen), with minor modifications (see Supplementary 1).
Real-time quantitative PCR. Quantitative PCR (qPCR) was performed using degenerate primers encompassing 
the V3 and V4 hypervariable regions of the bacterial 16 S rRNA gene (see Supplementary 1).
Library preparation and sequencing. Barcoded amplicon libraries for the analysis on the Illumina MiSeq plat-
form were generated using degenerate primers targeting the V3 and V4 hypervariable region of the bacterial 16 S 
rRNA gene and Nextera XT index kit (Illumina) (see Supplementary 1).
Sequence processing and data analysis. Analysis of the data generated on the Miseq System was carried out using 
the BaseSpace 16 S Metagenomics App (Illumina), whereas operational taxonomic unit (OTU) mapping to the 
Greengenes database (V.13.8) were performed using the Quantitative Insights Into Microbial Ecology (QIIME) 
platform (V.1.8.0). Sequences containing ambiguous or low-quality bases were filtered out using QIIME filter53. 
Remaining sequences were assigned to each sample according to the unique barcodes. Alpha diversity was esti-
mated using Shannon index metric.
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Metabolomics analysis. Stool samples extraction and preparation. Frozen feces (300 mg) were extracted 
with a solution of methanol\water (80:20) and the extract was divided in 3 aliquots for GC-MS1, H-NMR and 
LC-QTOF-MS analysis (see Supplementary 1).
Data processing. Chromatograms deriving from GC-MS and LC-QTOF-MS were processed to obtain a matrix 
of features present across all samples (see Supplementary 1).
Multivariate statistical analysis. Multivariate statistical data analysis was performed using SIMCA (version 14.0, 
Umetrics, Umea, Sweden). Principal components analysis (PCA) was used to identify the presence of outliers 
and to verify the influence of coffee, alcohol and smoke on metabolites composition of fecal samples. PCA is 
an unsupervised analysis that allows estimating and visualizing the distribution of the samples. Partial Least 
Square-Discriminant Analysis (PLS-DA) was performed to verify the influence of disease activity, disease local-
ization and medications on metabolites composition. Orthogonal Partial Least Square-Discriminant Analysis 
(OPLS-DA) was performed in order to classify samples and elucidate metabolites able to differentiate the classes.
Univariate statistical analysis. GraphPad Prism software (version 7.01, GraphPad Software, Inc., CA, USA) was 
used to perform the univariate statistical analysis of the data and Spearman correlations between the microbiome 
and the metabolome. To verify the significance of metabolites obtained using multivariate statistical analysis and 
to find differences in the microbiome, the Kruskall-Wallis Mann and the Whitney test were performed.
Availability of data and material. All Illumina sequence data and all microbiome-metabolome correla-
tion data from this study are available from the corresponding author on reasonable request. The datasets (clas-
sification, number of reads, percentages, Spearman correlations) supporting the conclusions of this work are 
included within the article as additional files (Supplementary information 2 and 3).
Ethical approval and consent to participate. The subjects gave informed consent, and the study 
protocol was approved by the Institution Ethics Committee (AOU Cagliari, Italy. Prot. NP/2014/3504; Prot. 
PG/2014/11480).
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